- PhD Student
- Department of Pathology (Dunedin)
- Research summary
- The emergence of drug tolerant persistors in response to targeted cancer therapy in lung cancer
- Demonstrating PATH201, PATH301, PATH302
- Associate Investigator, Maurice Wilkins Centre for Molecular Discovery (MWC) 2022-present
Patients with lung cancer initially respond dramatically to modern therapies, including targeted therapies. Unfortunately, these responses are often short-lived due to the development of drug tolerance and resistance. My research focuses on understanding how lung adenocarcinomas escape from targeted therapy via the phenomenon of drug tolerance. I am particularly interested in the involvement of long non-coding RNAs (lncRNAs) in this process.